Pivotal Period For Irlab And Its Parkinson’s Pipeline
Key Readout Coming For Mesdopetam
The Swedish biotech is well positioned with soon-to-be late-stage clinical assets, commercial validation and a strong pipeline, new CEO Richard Godfrey tells Scrip.
